Home › Research › Biomarkers
Ubiquitin Is Not a Blood Biomarker of an Early Cognitive Decline in the Polish Elderly
Oliwia McFarlane, Mariusz Kozakiewicz, Milena Wojciechowska, Kornelia Kędziora-Kornatowska. Current issues in molecular biology, 2023-03-16
Topic: Plasma and spinal-fluid biomarkers
No significant disparities in plasma ubiquitin levels for various levels of cognitive functioning were identified. Significantly higher plasma ubiquitin levels in women were found in comparison to men. No significant differences were found in ubiquitin concentrations based on age. Results suggest that ubiquitin does not meet the requirements for qualification as a blood biomarker of an early cognitive decline. In order to thoroughly evaluate the potential of research on ubiquitin in connection to an early neurodegenerative process, further studies are needed.
Key findings
- No significant disparities in plasma ubiquitin levels for various levels of cognitive functioning were identified.
- Significantly higher plasma ubiquitin levels in women were found in comparison to men.
- No significant differences were found in ubiquitin concentrations based on age.
- Results suggest that ubiquitin does not meet the requirements for qualification as a blood biomarker of an early cognitive decline.
- In order to thoroughly evaluate the potential of research on ubiquitin in connection to an early neurodegenerative process, further studies are needed.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Participants230
- Evidence strengthLow
How this study scored 50/100
Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomised / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multi-centre collaboration and free to read, so those were left out: it earned 28 of the 56 points we could judge it on, which is 50 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Current issues in molecular biology) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2023 — within 6 year(s) of the newest study here |
| Sample size | 2 / 4 | 230 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 36975530) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 28 / 56 | Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 28 of the 56 points we could judge it on is 50 out of 100. |
| Total | 50 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
APA 7th
McFarlane, O., Kozakiewicz, M., Wojciechowska, M., & Kędziora-Kornatowska, K. (2023). Ubiquitin Is Not a Blood Biomarker of an Early Cognitive Decline in the Polish Elderly. Current issues in molecular biology. https://doi.org/10.3390/cimb45030160
Vancouver
McFarlane O, Kozakiewicz M, Wojciechowska M, Kędziora-Kornatowska K. Ubiquitin Is Not a Blood Biomarker of an Early Cognitive Decline in the Polish Elderly. Current issues in molecular biology. 2023. doi:10.3390/cimb45030160. PMID: 36975530.
BibTeX
@article{mcfarlane2023-36975530,
author = {McFarlane, Oliwia and Kozakiewicz, Mariusz and Wojciechowska, Milena and Kędziora-Kornatowska, Kornelia},
title = {{Ubiquitin Is Not a Blood Biomarker of an Early Cognitive Decline in the Polish Elderly}},
journal = {Current issues in molecular biology},
year = {2023},
doi = {10.3390/cimb45030160},
pmid = {36975530},
url = {https://doi.org/10.3390/cimb45030160}
}
Related studies in Biomarkers
Also tagged “metabolic-syndrome”
304 studies in the library carry the topic tag “metabolic-syndrome”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 304 tagged studies.